CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($) $ in Thousands	3 Months Ended				6 Months Ended		12 Months Ended
	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2021	Mar. 31, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021
OPERATING ACTIVITIES:
Net income	$ 44,788	$ 32,901	$ 35,068	$ 45,394	$ 77,689	$ 80,462
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization					59,336	58,968
Non-cash impairment charges					0	2,754
Deferred income tax provision (benefit)					7,542	(4,907)
Share-based compensation					13,027	22,033
Amortization of debt issuance costs and expenses associated with debt refinancing					3,392	3,569
Non-cash lease expense					1,393	2,528
Loss on disposal of property and equipment					732	86
Gain from the sale of business	0		679		0	(42,197)
Change in fair value of contingent consideration and others					(5,799)	(385)
Changes in assets and liabilities:
Accounts receivable					(9,632)	10,802
Inventories					(17,576)	2,893
Prepaid expenses and other current assets					(4,120)	(8,061)
Other non-current assets					6,738	4,067
Accounts payable, accrued expenses and other current liabilities					(14,556)	27,277
Contract liabilities					774	0
Other non-current liabilities					(8,118)	482
Net cash provided by operating activities					110,822	160,371
INVESTING ACTIVITIES:
Purchases of property and equipment					(18,732)	(13,309)
Proceeds from sale of Extremity Orthopedics business					0	191,736
Acquired in-process research and development milestone					(4,742)	0
Net proceeds from swaps designated as net investment hedges					4,909	0
Cash paid for business acquisitions, net of cash acquired					0	(303,910)
Net cash used in investing activities					(18,565)	(125,483)
FINANCING ACTIVITIES:
Proceeds from borrowings of long-term indebtedness					23,000	2,200
Payments on debt					(23,000)	(102,200)
Payment of debt issuance costs					0	(249)
Purchases of treasury stock					(125,000)	0
Proceeds from exercised stock options					1,592	3,603
Cash taxes paid in net equity settlement					(23,204)	(3,844)
Net cash used in financing activities					(146,612)	(100,490)
Effect of exchange rate changes on cash and cash equivalents					(11,941)	(7,150)
Net decrease in cash and cash equivalents					(66,296)	(72,752)
Cash and cash equivalents at beginning of period		$ 513,448		$ 470,166	513,448	470,166	$ 470,166
Cash and cash equivalents at end of period	$ 447,152		$ 397,414		$ 447,152	$ 397,414	$ 513,448